Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 1094 results for infections

  1. Information and support: What is the clinical and cost effectiveness of information and support offered to parents and carers of babies who have received antibiotics for suspected or proven early-onset neonatal infection?

    neonatal infection? Any explanatory notes(if applicable) Source guidance details Comes from guidance Neonatal infection:...

  2. U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)

    NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .

  3. Immunisation: meningitis B (18 months) (IND226)

    This indicator covers the percentage of children who reached 18 months old in the preceding 12 months, who have received 2 primary doses and 1 booster dose of a meningitis B vaccine before the age of 18 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.

  4. Immunisation: meningitis B (8 months) (IND225)

    This indicator the percentage of babies who reached 8 months old in the preceding 12 months, who have received 2 doses of a meningitis B vaccine before the age of 8 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM207

  5. Immunisation: rotavirus (24 weeks) (IND224)

    This indicator covers the percentage of babies who reached 24 weeks old in the preceding 12 months, who have received 2 doses of rotavirus vaccine before the age of 24 weeks. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM206

  6. Immunisation: MMR (5 years) (IND218)

    This indicator covers the percentage of children who reached 5 years old in the preceding 12 months, who have received 1 dose of MMR between the ages of 1 and 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM200

  7. Immunisation: DTaP/IPV and MMR (5 years) (IND217)

    This indicator covers the percentage of children who have reached 5 years old in the preceding 12 months, who have received a reinforcing dose of DTaP/IPV and at least 2 doses of MMR between the ages of 1 and 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM199

  8. Immunisation: MMR (18 months) (IND216)

    This indicator covers the percentage of children who reached 18 months old in the preceding 12 months, who have received at least 1 dose of MMR between the ages of 12 and 18 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM198

  9. Immunisation: DTaP (8 months) (IND215)

    This indicator covers the percentage of babies who reached 8 months old in the preceding 12 months, who have received at least 3 doses of a diphtheria, tetanus and pertussis containing vaccine before the age of 8 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM197

  10. Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)

    NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care

  11. Interim process and methods for developing rapid guidelines on COVID-19 (PMG35)

    This guide sets out the process and methods used to develop rapid guidelines on COVID-19

  12. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    They include: : Infections, including vaginal infections and urinary tract infections. : Wound complications,...

  13. How can case-finding for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of hepatitis B and hepatitis C infection are identified and tested?

    or not specific groups at increased risk of hepatitis B and hepatitis C infection are identified and tested? Any explanatory notes(if...

  14. Acutely ill adults in hospital: recognising and responding to deterioration (CG50)

    This guideline covers how patients in hospital should be monitored to identify those whose health may become worse suddenly and the care they should receive. It aims to reduce the risk of patients needing to stay longer in hospital, not recovering fully or dying. It doesn’t specifically cover the care of children, patients in critical care areas or those in the final stages of a terminal illness.

  15. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.